ACSDKP SERUM CONCENTRATIONS VARY DURING CHEMOTHERAPY IN PATIENTS WITHACUTE MYELOID-LEUKEMIA

AcSDKP is a physiological negative regulator of cell proliferation in mammals, In Ara-C-treated mice its plasmatic concentrations decrease w hile the CFU-S start cycling. Infusion of AcSDKP protects these animal s from death by blocking the proliferation of primitive haemopoietic c ells. We measured AcSDKP serum concentrations in 20 AML patients durin g the course of high-dose cytoreductive treatment. We observed an earl y and sharp increase of AcSDKP during the induction treatment in 12 pa tients, reaching a peak during the initial 3 d of treatment in nine of them, These results are contrary to those observed in mice treated wi th high doses of Ara-C, They encourage further clinical investigation, and suggest that treatments with synthetic AcSDKP (Seraspenide) will perhaps have to be adjusted to the type of disease and the schedule of chemotherapy in order to optimize its myeloprotective effect.